🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Dear Colleagues at #ASCO25 with an exciting day today in GU Oncology We invite you to read our paper Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇 sciencedirect.com/science/articl… The 2024 Advanced Prostate Cancer Consensus Conference

FDA approves darolutamide for metastatic castration-sensitive prostate cancer fda.gov/drugs/resource… On June 3, 2025, the FDA🇺🇸 approved darolutamide for the treatment of metastatic castration-sensitive #ProstateCancer (mCSPC), expanding its previous indication in combination

Presented at #ASCO25 Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive #ProstateCancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes meetings.asco.org/abstracts-pres… The

#ASCO25 #ProstateCancer AMPLITUDE Trial 👉 PARPi in HRR+ mHSPC ▶️NIRA+AAP vs AAP ▶️ Better rPFS (HR 0.63; p=0.0001), particularly in those with BRCA1/2 alterations (HR 0.52; p<0.0001) Neeraj Agarwal, MD, FASCO 👏

A Magnificent end to #ASCO25 Huge thanks for ASCO for being the BEST host and for putting together yet another amazing meeting! Over 5⃣.5⃣K Posts on X #MEDTRACK ⚕️ Data

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study out on JCO ascopubs.org/doi/10.1200/JC… In this Phase 1 trial, pasritamig—a novel bispecific antibody targeting KLK2 on

Great Numbers out of #ASCO25 🚨 #MEDTRACK ⚕️

Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) ☢️for newly diagnosed localized #ProstateCancer presented at #ASCO25 meetings.asco.org/abstracts-pres… In a pivotal phase 3 trial, the addition

Health related quality of life (HRQoL) outcomes with darolutamide in the phase 3 ARANOTE Trial Presented at #ASCO25 meetings.asco.org/abstracts-pres… In the ARANOTE trial, darolutamide (DARO) plus androgen deprivation therapy (ADT) significantly improved patient-reported outcomes in men

Dear Colleagues, A warm invite to the Advanced Prostate Cancer Consensus Conference #APCCC26 in Beautiful Lugano Switzerland🇨🇭April 30-May 2, 2026 👉REGISTER HERE: apccc.org/apccc-2026/ In an era of rapid innovation and expanding treatment options for advanced #ProstateCancer

First-in-human results of terbium-161[161Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET) Presented at #ASCO25 meetings.asco.org/abstracts-pres… In this phase I/II trial, the novel radioligand therapy [¹⁶¹Tb]Tb-PSMA-I&T

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study ascopubs.org/doi/10.1200/JC… This phase I trial of pasritamig, a novel bispecific T-cell–engaging antibody targeting KLK2 in

The diverse roles of the circadian clock in #cancer nature.com/articles/s4301… 🕒 Circadian disruption is more than lost sleep—it's a cancer risk factor. New research shows links between clock misalignment and tumor biology, immunity, and DNA repair. Chronotherapy could be the

Impact of germline vs somatic BRCA mutation status on the efficacy of rucaparib vs physician’s choice in the TRITON3 study of patients with metastatic castration-resistant prostate cancer. (Poster in #ASCO25 ) meetings.asco.org/abstracts-pres… In the phase 3 TRITON3 study, rucaparib

Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial thelancet.com/journals/lanon… In the phase 3 CONTACT-02 trial, researchers evaluated the efficacy and safety of combining cabozantinib, a tyrosine

Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer aacrjournals.org/clincancerres/… Research has shown that around 30% of advanced #ProstateCancer patients have Homologous Recombination / DNA Damage

A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment sciencedirect.com/science/articl… This systematic review and meta-analysis

Association between serum 25-hydroxyvitamin D and #ProstateCancer in middle-aged and elderly Americans: a national population-based analysis of NHANES 2001–2018 bmccancer.biomedcentral.com/articles/10.11… A cross-sectional study utilizing data from the National Health and Nutrition Examination

First-in-human Study of a Dual-modality Prostate-specific Membrane Antigen–targeted Probe for Preoperative Positron Emission Tomography/Computed Tomography Imaging and Intraoperative Fluorescence Imaging in Prostate Cancer out in European Urology sciencedirect.com/science/articl… Study